Literature DB >> 14506009

Mutations in the DNA mismatch repair proteins MutS and MutL of oxazolidinone-resistant or -susceptible Enterococcus faecium.

Rob J Willems1, Janetta Top, Derek J Smith, David I Roper, Sarah E North, Neil Woodford.   

Abstract

Mutations in mutS and mutL, which encode DNA mismatch repair (MMR) proteins, can confer hypermutator phenotypes and may facilitate the emergence of mutational antibiotic resistance in bacteria. Linezolid-resistant enterococci (LRE) rarely emerge during therapy and contain mutations in 23S rRNA genes. As enterococci with defective MMR could be prone to the development of oxazolidinone resistance mutations, we investigated 13 clinical isolates of Enterococcus faecium, including 2 LRE, for mutations in mutSL. A 4,944-bp fragment spanning mutSL was sequenced from two pairs of linezolid-resistant (MICs, 64 micro g/ml) and linezolid-susceptible (MICs, 2 micro g/ml) E. faecium isolates (one pair from Austria and one pair from the United Kingdom) identical by pulsed-field gel electrophoresis. The pairs represented distinct strains in which linezolid resistance had emerged during therapy. The MutSL peptides of all four isolates had amino acid substitutions compared with the sequence of E. faecium strain DO (used for genome sequencing). These were Val352Ile (one pair of isolates only) and Met628Leu in MutS and Leu387Pro, Tyr406Phe, Thr415Ser, Phe427Leu, and Phe565Ile in MutL. The significance of these changes remains unknown; these isolates did not show a demonstrable hypermutator phenotype. The same substitutions were found in two of nine geographically diverse linezolid-susceptible enterococcal isolates; the other seven isolates had MutSL sequences identical to that of strain DO. Multilocus sequence typing revealed that all isolates with alternate MutSL peptides belonged to a distinct lineage of a prevalent E. faecium clonal complex, designated CC17. Further studies are needed to investigate the prevalence of these MutSL mutations and their possible roles in the emergence of E. faecium strains resistant to oxazolidinones and other antibiotic classes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506009      PMCID: PMC201155          DOI: 10.1128/AAC.47.10.3061-3066.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  Structure and function of mismatch repair proteins.

Authors:  W Yang
Journal:  Mutat Res       Date:  2000-08-30       Impact factor: 2.433

Review 2.  Molecular mechanisms of DNA mismatch repair.

Authors:  P Hsieh
Journal:  Mutat Res       Date:  2001-07-12       Impact factor: 2.433

3.  Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis.

Authors:  S H Marshall; C J Donskey; R Hutton-Thomas; R A Salata; L B Rice
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

4.  Crystal structure and ATPase activity of MutL: implications for DNA repair and mutagenesis.

Authors:  C Ban; W Yang
Journal:  Cell       Date:  1998-11-13       Impact factor: 41.582

5.  Stability of vancomycin-resistant enterococcal genotypes isolated from long-term-colonized patients.

Authors:  M J Bonten; M K Hayden; C Nathan; T W Rice; R A Weinstein
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

6.  Linezolid-resistant enterococci: report of the first isolates in the United Kingdom.

Authors:  Cressida Auckland; Louise Teare; Fiona Cooke; Mary E Kaufmann; Marina Warner; Graeme Jones; Kathy Bamford; Helen Ayles; Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

7.  Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.

Authors:  A P Johnson; L Tysall; M V Stockdale; N Woodford; M E Kaufmann; M Warner; D M Livermore; F Asboth; F J Allerberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-09-13       Impact factor: 3.267

8.  Variant esp gene as a marker of a distinct genetic lineage of vancomycin-resistant Enterococcus faecium spreading in hospitals.

Authors:  R J Willems; W Homan; J Top; M van Santen-Verheuvel; D Tribe; X Manzioros; C Gaillard; C M Vandenbroucke-Grauls; E M Mascini; E van Kregten; J D van Embden; M J Bonten
Journal:  Lancet       Date:  2001-03-17       Impact factor: 79.321

9.  Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA.

Authors:  G Obmolova; C Ban; P Hsieh; W Yang
Journal:  Nature       Date:  2000-10-12       Impact factor: 49.962

10.  Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low.

Authors:  Alexander J O'Neill; Ian Chopra
Journal:  J Antimicrob Chemother       Date:  2002-08       Impact factor: 5.790

View more
  16 in total

1.  Intact mutS in laboratory-derived and clinical glycopeptide-intermediate Staphylococcus aureus strains.

Authors:  Arunachalam Muthaiyan; Radheshyam K Jayaswal; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  Molecular detection of linezolid resistance in Enterococcus faecium and Enterococcus faecalis by use of 5' nuclease real-time PCR compared to a modified classical approach.

Authors:  Guido Werner; Birgit Strommenger; Ingo Klare; Wolfgang Witte
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

3.  Role of mutS and mutL genes in hypermutability and recombination in Staphylococcus aureus.

Authors:  Anne-Laure Prunier; Roland Leclercq
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

4.  Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.

Authors:  Andrea Endimiani; Martha Blackford; Elliot C Dasenbrook; Michael D Reed; Saralee Bajaksouszian; Andrea M Hujer; Susan D Rudin; Kristine M Hujer; Vincent Perreten; Louis B Rice; Michael R Jacobs; Michael W Konstan; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

5.  Molecular characterization of Rifr mutations in Enterococcus faecalis and Enterococcus faecium.

Authors:  Xiaoxing Du; Xiaoting Hua; Tingting Qu; Yan Jiang; Zhihui Zhou; Yunsong Yu
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

6.  Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from Korea.

Authors:  Kwan Soo Ko; Jin Yang Baek; Ji-Young Lee; Won Sup Oh; Kyong Ran Peck; Namyong Lee; Wee Gyo Lee; Kyungwon Lee; Jae-Hoon Song
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

7.  High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium.

Authors:  Helen L Leavis; Rob J L Willems; Janetta Top; Marc J M Bonten
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

8.  The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates.

Authors:  Silke Besier; Johannes Zander; Barbara C Kahl; Peter Kraiczy; Volker Brade; Thomas A Wichelhaus
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

9.  Long-Term Colonization Dynamics of Enterococcus faecalis in Implanted Devices in Research Macaques.

Authors:  Mia T Lieberman; Daria Van Tyne; JoAnn Dzink-Fox; Eric J Ma; Michael S Gilmore; James G Fox
Journal:  Appl Environ Microbiol       Date:  2018-08-31       Impact factor: 4.792

10.  Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.

Authors:  Boubakar B Ba; Corinne Arpin; Branly Bikie Bi Nso; Véronique Dubois; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2010-01-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.